Annexin II has been identified as a human cytomegalovirus (HCMV)-binding protein, shown to be a component of purified virions and proposed as a cellular receptor for the virus. In addition, annexin II is capable of associating with the major HCMV envelope glycoprotein, gB (gpUL55). As one approach to examine the role of annexin II in virus entry, a high-titre polyclonal annexin IIspecific antibody was produced and its effects in virus entry and cell-to-cell spread assays were tested. This anti-annexin II serum recognized virion and cell surface annexin II and annexin IIderived peptides. Recombinant annexin II, with characteristic calcium-and phospholipid-binding activities, was also examined. Pretreatment of cells, virions or both with polyclonal anti-annexin II serum, affinity-purified anti-annexin II antibodies or recombinant annexin II protein prior to infection was inconsequential to the entry of HCMV into fibroblasts. HCMV was also able to dosedependently penetrate annexin II-deficient 293 cells. Furthermore, the spread of HCMV from cell to cell was not inhibited in the presence of polyclonal anti-annexin II antibodies or exogenous annexin II protein. These experiments do not support a direct role of annexin II in virus entry or spread. Alternative roles for the gB-annexin II interaction are proposed.
Introduction
The initial interaction between human cytomegalovirus (HCMV) and host cells is mediated by cell surface heparan sulfate proteoglycans (HSPGs) (Compton et al., 1993 ; Neyts et al., 1992) . After stable attachment to the cell surface, virions undergo a pH-independent fusion event with the host cell plasma membrane (Compton et al., 1992) whereby the viral nucleocapsid is deposited in the cell cytoplasm. The events between initial binding of HCMV to HSPGs and direct fusion of the viral envelope with the plasma membrane are poorly understood, although these events probably involve multiple cellular and viral components (Compton, 1995) . A number of cellular molecules have been postulated to serve as receptors for HCMV that probably function downstream of the initial HSPG-mediated concentration of virions at the cell surface. These include CD13 (aminopeptidase N) (Soderberg et al., 1993) , a 92n5 kDa phosphoprotein (Keay & Baldwin, 1992 ; Keay et al., 1989) and annexin II (previously known as a 30-34 kDa protein) (Adlish et al., 1990 ; Nowlin et al., 1991 ; Taylor & Cooper, 1990) .
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Fax j1 608 262 8418. e-mail tcompton!facstaff.wisc.edu Annexin II, a calcium-, phospholipid-and actin-binding protein (Blackwood & Ernst, 1990 ; Crompton et al., 1988 ; Evans & Nelsestuen, 1994 ; Moss, 1992 ; Reutelingsperger, 1994) , has been shown to bind specifically, saturably and with high affinity to HCMV virions (Wright et al., 1994) . Immunocytochemical analysis localized annexin II to the envelope of virions (Wright et al., 1995) . We recently reported that annexin II binds HCMV through its calcium-dependent phospholipidbinding ability, as well as through a calcium-independent mechanism, and discovered that annexin II is capable of forming a physical association with the major viral envelope glycoprotein (gB ; gpUL55) (Pietropaolo & Compton, 1997) . However, the role that annexin II, possibly in conjunction with gB, may play to facilitate HCMV infection is unknown.
Annexin II has a broad cellular localization including the exterior of the plasma membrane. Cell types expressing annexin II on the extracellular face of the plasma membrane include fibroblasts (this communication ; see Fig. 2 ), endothelial cells (Chung & Erickson, 1994 ; Hajjar et al., 1994 ; Wright et al., 1994) , epithelial cells (Ma et al., 1994) and lymphoma cells (Tressler et al., 1993 ; Yeatman et al., 1993) . Cell surface annexin II has been ascribed receptor functions in a variety of biological systems (Chung & Erickson, 1994 ; Hajjar et al., 1994 ; Tressler et al., 1993) . For example, annexin II has been identified as a Production and characterization of recombinant annexin II. The human annexin II cDNA (provided by K. Hajjar ; Hajjar et al., 1994) was cloned into the Novagen bacterial expression vector pET-28c and transformed into Escherichia coli BL21(DE3). This construction added 33 amino acids to the amino terminus of the recombinant protein, including a His ' tag for purification using Ni# + -affinity chromatography. Insoluble annexin II was collected and purified as per the manufacturer's instructions (Novagen) in the presence of 6 M urea, dialysed against PBS, and used for antibody generation in rabbits. Urea-denatured purified recombinant annexin II was renatured by dialysis against 100 mM NaCl, 1 mM EGTA, 1 mM dithiothreitol and 20 mM imidazole, pH 7n5 (Jost et al., 1994) , dialysed against PBS and stored at k70 mC. The physico-chemical properties of renatured recombinant annexin II were tested by measuring the change in tryptophan fluorescence after calcium binding and calciumdependent phospholipid binding. In brief, the fluorescence emission spectrum of a 5 µM solution of annexin II was measured in the presence and absence of 1 mM calcium as previously described (Marriott et al., 1990) . Additionally, refolded annexin II was used in liposome cosedimentation experiments as described (Blackwood & Ernst, 1990) .
Protease digestion of recombinant annexin II. Purified refolded recombinant annexin II was digested with sequencing grade endoproteinase Glu-C (Sigma) at varying ratios (w\w) of protease to protein. Digestions were performed in 50 µl of 50 mM NH % HCO $ (Sigma), pH 7n8 at 37 mC for 16 h. Parallel samples were resolved through SDS-15 % PAGE under reducing conditions and either silver-stained or electrotransferred to nitrocellulose and immunoblotted with polyclonal anti-annexin II.
SDS-PAGE and immunoblotting.
Final buffer composition for SDS-PAGE samples was 2 % SDS, 62n5 mM Tris, pH 6n8 and 10 % glycerol. Reduced samples also contained 5 % β-mercaptoethanol. After resolution in polyacrylamide gels, proteins were transferred to nitrocellulose membranes (Millipore) and probed with primary antibodies. Secondary antibodies were goat anti-mouse or goat anti-rabbit conjugated to horseradish peroxidase (Pierce). Immunoblots were reacted with SuperSignal Ultra chemiluminescence reagents (Pierce) and imaged using a Bio-Rad model GS-525 Molecular Imager. Densitometric analysis of phosphorimages was carried out using Bio-Rad Molecular Analyst software as per the manufacturer's instructions.
Entry assays.
Approximately 2i10& IF or 293 cells were seeded into 12-well dishes containing sterile coverslips 24 h prior to the assay. Subconfluent cell monolayers were washed twice with ice-cold PBS, placed on ice and incubated for 90 min at 4 mC in 200 µl serum-free DMEM plus 0n3 % glutamine and 1 % PSF (SFDMEM) alone or SFDMEM with AD169 at an m.o.i. of approximately 0n1-0n5. After the 90 min attachment period, cells were washed with cold PBS, bathed in prewarmed SFDMEM and incubated at 37 mC for 30 min to allow synchronized penetration of bound virions. Any extracellular virus remaining after the 37 mC incubation period was inactivated with a low pH wash (40 mM citric acid, 10 mM KCl, 135 mM NaCl, pH 3n0), followed by an overnight incubation at 37 mC in DMEM supplemented with 2n5 % FBS, 1 % PSF and 0n3 % glutamine (MMDMEM). At 18-20 h post-infection cells were washed with PBS-MC (PBS, 1 mM MgCl # , 0n1 mM CaCl # ) and fixed with 3 % paraformaldehyde (Sigma) in PBS for 20 min.
For some inhibition studies, cells were pretreated with various concentrations of anti-annexin II, anti-p11, ε-aminocaproic acid (ε-ACA), or refolded recombinant annexin II protein in SFDMEM for 1 h at 4 mC before inoculation with virus. After pretreatment, HCMV strain AD169 was added at an m.o.i. of approximately 0n1-0n5 and cells were treated as described above. For homocysteine (HC) inhibition of the t-PA-binding site on annexin II, IF cells were pretreated for 18-20 h at 37 mC with various concentrations of HC (Sigma) in CDMEM. The cells were subsequently washed with cold PBS, chilled on ice and inoculated with AD169 as described above.
In other experiments, HCMV, at an approximate m.o.i. of 0n5-1, was pretreated in SFDMEM with antibodies or recombinant annexin II protein for 1 h at room temperature with agitation. Treated virions were then inoculated onto PBS-washed cell monolayers and incubated at 37 mC for 1 h. Exogenous virus was inactivated with low pH buffer and infected cell monolayers were processed as described above.
Focus expansion assays. IF cells were seeded onto sterile coverslips in 12-well dishes at a concentration of 8i10% cells per well. The next day, monolayers were washed twice with cold PBS, chilled on ice for 5 min and inoculated with HCMV at an m.o.i. of 0n1-0n5. In some experiments, the virus inoculum was pre-incubated with antibodies for 1 h at room temperature prior to infection. HCMV was allowed to attach to cells for 90 min at 4 mC, after which the monolayers were washed once with PBS, bathed in prewarmed SFDMEM and shifted to 37 mC for 30 min. Cells were washed with low pH buffer to inactivate any remaining exogenous virus and incubated in MMDMEM containing 10 µg\ml heparin (to neutralize any extracellular progeny ; Sigma) and various antibody dilutions. This medium was replenished every other day for 5 days, at which time cells were washed with PBS-MC, fixed with 3 % paraformaldehyde in PBS for 20 min, and processed for immuno- Annexin II is not essential for HCMV entry Annexin II is not essential for HCMV entry fluorescence. The number of nuclei in 15 foci were counted per treatment and averaged.
BIAI
Immunofluorescence. Fixed cells were permeabilized with 0n1% Triton-X 100 in PBS for 10 min, or left intact for cell surface staining, washed twice for 5 min with PBS-G (PBS, 0n2 % gelatin) and inverted on 75 µl drops of rabbit anti-IE or anti-annexin II diluted in PBS-G for 1 h. Three more 5 min washes in PBS-G were performed before cells were inverted on 75 µl drops of goat anti-rabbit conjugated to either fluoroscein isothiocyanate (FITC) or rhodamine plus 1 µg\ml of Hoechst 33258 dye (bisbenzimide ; Sigma). After staining, cells were washed three times for 5 min in PBS-G, once in PBS-G plus 0n1 % Tween-20 and then inverted on drops of 20 % Airvol (Air Products) in PBS. Fluorescent signals were detected with a Nikon Optiphot-2 microscope using the appropriate filters. Percent control infection was calculated by first determining the percentage of infected nuclei [IE-positive nuclei\total (Hoechst-positive) nuclei] per treatment and dividing this number by the percent infection obtained in the control treatment.
Results

HCMV carries annexin II and p11
Annexin II exists in two distinct physical forms, as a monomer and as a heterotetramer composed of two annexin II monomers and two p11 proteins (annexin II # p11 # ). We wished to determine which form of annexin II was present in virions, since each form functions differently in cells. Immunoblot analysis of gradient-purified AD169 virions confirms previous reports that annexin II is a component of HCMV (Pietropaolo & Compton, 1997 ; Wright et al., 1995) (Fig. 1 ). As shown in Fig. 1 , p11 is also detected in virions, suggesting that the form of annexin II carried by HCMV may be heterotetrameric instead of, or in addition to, monomeric. Furthermore, annexin II and p11 were also detected in virions derived from the low passage clinical isolate, Toledo (data not shown), indicating that the presence of annexin II and p11 in strain AD169 is not simply the result of prolonged passage in fibroblast cells. Additionally, to assess the purity of our virion preparations and the specificity of the anti-annexin II and anti-p11 antibodies, AD169 virions were immunoblotted with an antibody to the abundant cytoplasmic 90 kDa heat shock protein (Hsp90) and the polyclonal pre-immune sera. As shown in Fig. 1 , Hsp90 was undetectable in virions, confirming that the annexin II and p11 detected in HCMV are not merely cellular contaminants.
To test HCMV for the presence of annexin II # p11 # , virions were lysed and immunoprecipitated with anti-annexin II, followed by immunoblot analysis using both anti-annexin II and anti-p11 antibodies. Anti-annexin II co-immunoprecipitated annexin II and p11 from virion lysates (data not shown), demonstrating that annexin II is present in virions as a tetramer. This novel finding is significant in that the annexin II tetramer can act as a bivalent molecule by binding two phospholipid membranes simultaneously and bringing them into close apposition (Burgoyne, 1988 ; Drust & Creutz, 1988) . This type of aggregating event is considered necessary for subsequent fusion reactions to take place. Therefore, we thought it reasonable that tetrameric annexin II, present at the virus or cell surface, may facilitate HCMV entry into cells by bridging the viral and cellular lipid bilayers as a prelude to the direct fusion event HCMV catalyses in order to penetrate host cells.
Characteristics of polyclonal anti-annexin II
(i) Cell surface staining. We generated a high-titre polyclonal anti-annexin II serum from recombinant annexin II protein that specifically detects an approximately 38 kDa protein from cell lysates (Pietropaolo & Compton, 1997) . As demonstrated in Fig. 1 , this antibody is capable of immunoblotting annexin II present in HCMV virions and, as previously reported, immunoprecipitates annexin II from both cells and virions (Pietropaolo & Compton, 1997) . A requisite criterion of the annexin II antiserum for use in virus entry inhibition studies would be that it recognize native cell surface annexin II. As shown in Fig. 2 (a) , our polyclonal anti-annexin II antibody, but not pre-immune serum (data not shown), recognizes annexin II present at the surface of IF cells, thereby rendering it a useful tool to explore the role of extracellular annexin II during HCMV entry into host cells.
(ii) Immune recognition of annexin II-derived peptides. We next determined the range of epitopes recognized by our polyclonal anti-annexin II serum by immunoblotting annexin II-derived R. Pietropaolo and T. Compton R. Pietropaolo and T. Compton peptides. Purified recombinant annexin II protein was digested with endoproteinase Glu-C and the resulting peptides were separated by SDS-15 % PAGE. Parallel samples were either silver-stained, to visualize total peptides, or immunoblotted with anti-annexin II to determine the proportion of fragments recognized by the serum (Fig. 2 b) . As shown in Fig. 2 (b) , the annexin II antibody recognized the majority of annexin IIderived peptide fragments, indicating that the antiserum contains multiple immunoglobulin species that recognize multiple and dispersed annexin II epitopes. The anti-annexin II serum detects protein of approximately 41 kDa when recombinant annexin II is left undigested and does not recognize endoproteinase Glu-C in digestions lacking annexin II (data not shown). Combined with the immunofluorescence results, our anti-annexin II polyclonal serum is capable of recognizing cell surface native annexin II as well as multiple epitopes along the length of the protein, making it an ideal reagent for use in antibody-inhibition studies designed to block cell surface annexin II.
Antibody-blocking experiments have no effect on HCMV entry into fibroblasts
Based on the above criteria, we tested if our polyclonal antibody, a reagent capable of recognizing multiple epitopes on native protein, would compete for HCMV entry. We also tested the inhibitory activity of an anti-p11 monoclonal antibody. Our laboratory has generated a rapid and sensitive virus entry assay that utilizes indirect immunofluorescent detection of the HCMV major immediate early protein (IE72) to accurately quantify percent virus penetration into cells (Boyle & Compton, 1998) . The results presented in Fig. 3 (a) demonstrate that treatment of fibroblasts with either antiannexin II affinity purified antibodies or anti-p11 monoclonal antibodies, prior to the addition of HCMV, had virtually no effect on the ability of virus to enter these cells. Additionally, identical experiments utilizing dilutions of anti-annexin II serum to pretreat fibroblasts prior to HCMV infection yielded the same results (Fig. 3 b) . In contrast, pretreatment of cells with BIBA Annexin II is not essential for HCMV entry Annexin II is not essential for HCMV entry Fig. 3 . Penetration of HCMV into cells pretreated with anti-annexin II or anti-p11 antibodies. IF monolayers grown on coverslips were pretreated with various concentrations of anti-annexin II or p11 antibodies (a) or antiannexin II polyclonal serum dilutions (b) for 60 min at 4 mC, prior to infection with HCMV. Pretreatment with 10 µg/ml heparin was included in each experiment as a treatment known to block HCMV infection. Penetration was monitored by immunofluorescence using an antibody to an immediate early antigen, IE72, which localizes to nuclei, followed by FITC-conjugated secondary antibody plus Hoechst dye. Percent control infection was calculated by dividing the number of IE-positive nuclei by the number of Hoechst-stained nuclei, and standardizing this value to the control, which was set at 100 %. Each value represents the average of duplicate samples and error bars indicate the standard deviation between values. , Anti-annexin II ; >, anti-p11 ; $, pre-immune serum. Duplicate heparin treatments included in each experiment are indicated by unshaded and shaded bars.
10 µg\ml heparin, a sulfated polysaccharide that blocks the initial binding of HCMV to host cell HSPGs (Compton et al., 1993 ; Neyts et al., 1992) , blocked HCMV penetration (Fig. 3) .
Inactivation of two characterized binding sites on cell surface annexin II has no effect on HCMV entry into fibroblasts
As an alternative to antibody inhibition studies, we performed experiments to inactivate two characterized ligandbinding sites on annexin II and monitored the resulting effect on HCMV penetration. Annexin II has been characterized as an endothelial cell surface receptor for both t-PA and PLG (Hajjar et al., 1994) . Binding of PLG and t-PA to annexin II is noncompetitive and occurs through two sites on annexin II which can be differentially inactivated (Hajjar et al., 1994) . PLG activation by annexin II can be inhibited by 97 % with 10 mM ε-ACA (Cesarman et al., 1994) , a lysine analogue that interferes with kringle-associated lysine-binding sites on PLG that interact with carboxy-terminal lysine residues on annexin II (Hajjar et al., 1986) . In contrast, t-PA binds annexin II through a linear sequence and this interaction is sensitive to HC treatment (Hajjar, 1993) . An 18 h treatment of endothelial cells with 1-7n5 mM HC resulted in a 50-65 % decrease in specific binding of t-PA to annexin II (Hajjar, 1993) . To determine if inactivation of these known binding sites on annexin II would inhibit HCMV entry into permissive cells, IF cells were treated with either ε-ACA or HC followed by HCMV infection. Differential inactivation of annexin II-binding sites had no effect on HCMV entry (Fig. 4) , while soluble heparin treatment reduced HCMV penetration into fibroblasts on average by 93 %, indicating that HCMV does not utilize either t-PA-or R. Pietropaolo and T. Compton R. Pietropaolo and T. Compton PLG-binding sites present on cell surface annexin II during entry.
Entry into annexin II-deficient 293 cells
Human 293 cells have been reported to contain very low levels of annexin II protein (Hajjar et al., 1994 ; Pietropaolo & Compton, 1997) . Equal amounts of membrane proteins prepared from IF and 293 cells were electrophoresed, immunoblotted with anti-annexin II and subjected to densitometric analysis in order to quantify the relative levels of annexin II present in both cell types (Fig. 5 a, b) . 293 cells contain just 7n5 % as much annexin II per µg membrane protein as IF cells (Fig. 5 b) . We therefore examined HCMV entry into annexin IIrich fibroblasts and annexin II-deficient 293 cells. Penetration BIBC into cells was quantified through immunoblot detection and phosphorimage analysis of the immediate early protein (IE72) from infected cell lysates harvested 18-24 h post-infection. HCMV was able to penetrate annexin II-deficient 293 cells in a dose-dependent manner, demonstrating that high levels of annexin II on host cells is not required for HCMV entry (Fig.  5 c) . Furthermore, HCMV was able to enter 293 cells as efficiently as the normal host IF cells, suggesting that either cell surface annexin II is not serving as a receptor for HCMV on fibroblasts or 293 cells, or that very low quantities are sufficient and\or compensated for by virion annexin II.
Viral surface annexin II is dispensable for HCMV entry into fibroblasts
While the above results suggested that cell surface annexin II is not required for HCMV entry into fibroblasts, the role of viral surface annexin II was not addressed. To test the importance of virus-associated annexin II during entry into cells, HCMV was pretreated with antibodies to annexin II and then inoculated onto IF monolayers. Penetration of HCMV into cells was quantified through an indirect immunofluorescent assay for IE72. Pretreatment of HCMV virions with high concentrations of polyclonal anti-annexin II, affinity purified anti-annexin II antibodies or monoclonal anti-p11 antibodies had no effect on the ability of the virus to enter IF cells (Fig. 6 a,  b) . In contrast, neutralizing anti-glycoprotein H antibody (14-4b) did inhibit HCMV penetration into cells in a dosedependent manner. We have also generated a refolded recombinant version of human annexin II that retains key features characteristic of native protein. Spectroscopic analysis of renatured annexin II protein revealed the characteristic calcium-induced blue-shift in tryptophan fluorescence (Marriott et al., 1990 ) (data not shown), indicating that our recombinant version binds calcium. Refolded annexin II also displayed the well-described ability to bind and cosediment with phosphatidylserine liposomes in the presence of calcium, demonstrating that the recombinant protein retains its ability to bind negatively charged phospholipids (data not shown). We next used our active, recombinant annexin II to block HCMV entry into IF cells. Preincubation of HCMV virions with recombinant annexin II protein neither augmented nor blocked entry of the virus into IF cells (Fig. 6 c) . The ability of anti-annexin II-treated, anti-p11-treated and annexin II-treated HCMV to penetrate fibroblasts with no loss in efficiency strongly indicates that viral surface annexin II is not crucial for entry of HCMV into fibroblast cells.
Treatment of both cells and virions with antibodies to annexin II and recombinant annexin II protein
Since annexin II is present in two pools, at the cell and virus surface, we pretreated both HCMV virions and IF cells prior to conducting entry assays in order to neutralize all surface annexin II present in the system. Treatment of both cells and virions with anti-annexin II antibodies did not affect HCMV entry into host cells (Fig. 7 a) . Similarly, when both cells and virions were preincubated with recombinant annexin II protein, HCMV was able to enter cells with no loss in efficacy (Fig. 7 b) . Cumulatively, our data support the conclusion that annexin II, either at the cell surface or in the viral envelope, is not required for entry of HCMV into fibroblast cells.
Effect of anti-annexin II on cell-to-cell spread of HCMV
A recent report has implicated annexin II in gB-mediated cell-to-cell fusion between gB-expressing transfectants with non-gB-expressing cells (Bold et al., 1996) . We next tested the role of annexin II during the cell-to-cell spread of a natural HCMV infection. To this end we have developed a rapid focus expansion assay that is quicker than traditional plaque assays, and allows for precise quantification of the number of cells comprising an infectious centre (foci). As a control, we first BIBD R. Pietropaolo and T. Compton R. Pietropaolo and T. Compton   Fig. 8 . Focus expansion assays. After HCMV infection of IF cells, monolayers were incubated with various concentrations of anti-annexin II antibodies. Infections were allowed to proceed for 5 days, and were performed in the presence of 10 µg/ml heparin to neutralize progeny extracellular virus. The number of cells in each infectious centre was quantified through indirect immunofluorescent detection of the major immediate early protein (IE72) of fixed and stained monolayers. Bars represent the average size of 15 infectious centres per treatment. The neutralizing anti-gB monoclonal antibody 9-3 was used at a concentration of 100 µg/ml as a positive control.
pretreated HCMV virions with anti-annexin II antibodies before titrating infectivity. This treatment did not affect the size of resultant infectious foci (data not shown), further establishing that virion-associated annexin II is not important for entry of the virus into cells. These results contradict a previous report (Wright et al., 1995) where preincubation of HCMV with a polyclonal anti-annexin II serum resulted in a diminution (54 %) in the number of plaques formed when compared to control-treated virions. The cause of this discrepancy is unclear.
To define the role that cell surface annexin II may play during the direct cell-to-cell spread of HCMV infection, HCMV was allowed to infect IF monolayers which were subsequently incubated continually in the presence of antiannexin II or control antibodies. Medium was replenished every other day with antibodies and contained 10 µg\ml heparin in order to neutralize exogenous virus. As shown in Fig. 8 , HCMV was able to efficiently spread from cell to cell in the presence of high concentrations of anti-annexin II antibodies. In contrast, the neutralizing anti-gB antibody 9-3 almost completely abrogated the formation of infectious foci in this assay. These data suggest that cell surface annexin II, in contrast to cell surface gB, is not required for direct cell-to-cell spread of HCMV infection in fibroblasts.
Discussion
This is the first report to directly examine a potential functional role for annexin II in HCMV entry. HCMV recognition of a 30-34 kDa cellular protein was reported in 1990 (Adlish et al., 1990 ; Taylor & Cooper, 1990) and this protein was identified as annexin II in 1994 (Wright et al., 1994) . Since that time, it has been difficult to assess the functional significance of annexin II in HCMV biology primarily due to its very broad cellular distribution. We approached the question of functionality by testing the inhibitory activity of a high titre anti-annexin II antiserum. We found that HCMV could enter cells treated with relatively high concentrations of anti-annexin II. Similarly, virions or cells plus virions treated with the antiserum or purified antibodies were also unimpaired to any measurable degree in sensitive virus entry assays. Since our antiserum was generated by immunization with prokaryotically produced recombinant annexin II, it was therefore critical to the interpretation of these experiments that the antiserum recognize annexin II in its native state and in particular, it was crucial that the antibody react with annexin II present on the exterior of the cell. We previously published that this antiserum efficiently immunoprecipitated annexin II and annexin II-gB complex derived from non-denatured detergent lysates (Pietropaolo & Compton, 1997) . In this report, we demonstrate that the antiannexin II serum recognized annexin II localized to the plasma membrane (Fig. 2 a) . Furthermore, it reacted with multiple epitopes present on a large number of endoproteolytically derived annexin II peptides (Fig. 2 b) . However, it was unable to block one prescribed annexin II function, that of phospholipid binding (data not shown), nor were we able to definitively establish if it blocked the gB-annexin interaction.
There are several possible interpretations for the lack of blocking activity of the anti-annexin II serum in virus entry. First, it is possible that a critical functional epitope(s) involved in entry is not recognized by the antiserum. However, the fact that the serum does recognize native protein and virtually every peptide generated by extensive proteolytic digestion suggests the presence of a large repertoire of immunoglobulins. Some blocking activity would likely be expected by steric hindrance whereas we did not observe any inhibition. Alternatively, critical epitopes needed for HCMV entry were recognized but blockage of annexin II is compensated for by different receptor usage. This hypothesis evokes the concept of complete compensation since there was no effect whatsoever on annexin II-blocked entry assays. Given the broad cellular tropism of HCMV and the vast glycoprotein coding capacity, it is conceivable, although as yet unparalleled in virus systems, that alternative ligand-receptor pathways are operative. A third possibility is that annexin II itself lacks a direct functional capacity in entry but rather serves a supporting role. For example, we have shown that annexin II is associated with gB and that gB serves as a viral ligand binding to cellular receptors needed for virus entry (Boyle & Compton, 1998) . Of great interest is the fact that this interaction of gB with its cellular receptor initiates intracellular signalling and activation of the interferon responsive pathway (Boyle et al., 1999) , a recently described cellular consequence to HCMV infection (Zhu et al., 1997) . Since gB is also critical for penetration and fusion, a highly regulated process which may be triggered by conformational changes, annexin II may serve a structural role by maintaining gB in a fusion-inactive, receptor-binding conformation. It is also possible that critical epitopes involved in the gB-annexin II protein-protein interaction may not be accessible to antibodies.
Given the caveats and theoretical limitations of antibody blocking experiments, two additional experimental venues were examined. First, we tested chemical inactivation of two characterized binding sites for annexin II biological ligands, t-PA and PLG. Mirroring the results of antibody blocking experiments, HCMV was unaffected by conditions that block binding and conversion of t-PA and PLG into plasmin. These data suggest that neither the binding sites for these ligands nor the plasmin assembly activity supported by annexin II is involved in HCMV entry. Finally, we examined the ability of HCMV to enter annexin II-deficient 293 cells. Confirming published reports, we found that 293 cells possessed 93 % less annexin II than did fibroblast cells, whereas virus entry was equal to that of fibroblasts. It does not seem likely that the low annexin II levels in 293 cells would be sufficient to support HCMV entry, since Scatchard analysis of both virions (Taylor & Cooper, 1990 ) and the gB ligand (Boyle & Compton, 1998) suggest highly abundant receptor-binding sites. Thus, our evidence does not support an essential role for annexin II in HCMV entry. Wright et al. (1995) reported modest inhibitory activity of a polyclonal antibody in plaque reduction assays while Bold et al. (1996) found that transfectants expressing wild-type HCMV gB were impaired in cell-to-cell fusion when anti-annexin II was introduced into the fusion assay. These findings suggest that annexin II may be involved in cell-to-cell spread of HCMV. Using a very sensitive focus expansion assay, we found that neutralization of cell surface annexin II with high concentrations of polyclonal antibodies was inconsequential for direct cell-cell spread. It is possible that the role of annexin II in HCMV entry, as well as the entry mechanism itself, varies from cell type to cell type. This could explain the discrepancy between our results, utilizing fibroblasts, with the gB transfectant studies, which used astrocytoma cells. The discrepancy over the role of annexin II in HCMV plaque formation is more difficult to explain. It is unclear why we were unable to reproduce the results of Wright et al. (1995) , who also used a polyclonal anti-annexin II antibody, given that we produced a high-titre, multiple epitope recognizing anti-annexin II serum.
In addition to the cell and virus surfaces, annexin II is found in multiple intracellular locations. While monomeric annexin II is soluble and cytoplasmic, heterotetrameric annexin II (annexin II # p11 # ) has been localized to the extracellular surface of cells (Tressler & Nicolson, 1992 ; Yeatman et al., 1993) , the cortical cytoskeleton (Osborn et al., 1988 ; Thiel et al., 1992 ; Zokas & Glenney, 1987) and endosomal membranes (Harder & Gerke, 1993 , 1994 . Since heterotetrameric annexin II binds tightly to cytoskeletal components in a calcium-dependent manner, and can bind and annex two separate lipid bilayers (in contrast to monomeric annexin II), it has been suggested that annexin II # p11 # may be mediating membrane-membrane and membrane-cytoskeletal interactions that would be crucial to vesicular membrane traffic. HCMV undergoes extensive fusion reactions within infected host cells during acquisition of primary and final cell-derived lipid envelopes -processes that are thought to be influenced by viral glycoproteins. Interestingly, endosomes, which contain high quantities of annexin II, are one proposed final envelopment site for HCMV (Tooze et al., 1993) . It is therefore attractive to hypothesize that annexin II, perhaps through its interaction with glycoprotein B, may be facilitating an intracellular step in the virus life-cycle, such as acquisition of the final lipid envelope or egress from the cell along cytoskeletal elements. Currently, we are investigating the possibility that annexin II and gB associate within infected cells in a fashion critical for HCMV infectivity.
